Barbara Depreter

Journal Article
A1
open access

Nidogen-1, a player in KMT2A-rearranged pediatric acute myeloid leukemia

Jolien Vanhooren (UGent) , Larissa Deneweth (UGent) , Luca Pagliaro, Zhiyao Ren (UGent) , Mariateresa Giaimo, Rafaella Zamponi, Giovanni Roti, Barbara Depreter, Mattias Hofmans (UGent) , Barbara De Moerloose (UGent) , et al.

(2025) INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 26(7).

Add to list

Nidogen-1, a novel player in KMT2A-rearranged pediatric acute myeloid leukemia patients, expressed in the leukemic stem cell

Jolien Vanhooren (UGent) , Larissa Deneweth (UGent) , Luca Pagliaro, Zhiyao Ren (UGent) , Barbara Depreter, Mattias Hofmans (UGent) , Barbara De Moerloose (UGent) and Tim Lammens (UGent)

(2024) BLOOD. In Blood 144(Supplement 1). p.6134-6135

Add to list

Ultra-deep sequencing and single cell multi-omics characterize measurable residual disease and identify therapy-survived clone in pediatric acute myeloid leukemia

Borhan R. R Saeed, Anastasia Saboli, Anna Rehammar, Adam Molnar, Erik Delsing Malmberg, Barbara Depreter, Giti Shah Barkhordar, Barbara De Moerloose (UGent) , Tim Lammens (UGent) , Lars Palmqvist, et al.

(2024) BLOOD. In Blood 144(Supplement 1). p.4994-4995

Add to list

Conference Paper
C3
open access

Deciphering the non-coding landscape of pediatric acute myeloid leukemia

Jolien Vanhooren (UGent) , Laurens Van Camp (UGent) , Barbara Depreter, Martijn de Jong (UGent) , Anne Uyttebroeck, An Van Damme, Laurence Dedeken, Marie-Françoise Dresse, Jutte van der Werff ten Bosch, Mattias Hofmans (UGent) , et al.

(2022) BVK-SBP Congress 2022, Abstracts.

Add to list

Journal Article
A1
open access

TARP as antigen in cancer immunotherapy

Jolien Vanhooren (UGent) , Charlotte Derpoorter (UGent) , Barbara Depreter, Larissa Deneweth (UGent) , Jan Philippé (UGent) , Barbara De Moerloose (UGent) and Tim Lammens (UGent)

(2021) CANCER IMMUNOLOGY IMMUNOTHERAPY. 70. p.3061-3068

Add to list

Deciphering molecular heterogeneity in pediatric AML using a cancer vs. normal transcriptomic approach

Barbara Depreter, Barbara De Moerloose (UGent) , Karl Vandepoele (UGent) , Anne Uyttebroeck, An Van Damme, Eva Terras (UGent) , Barbara Denys (UGent) , Laurence Dedeken, Marie-Francoise Dresse, Jutte Van der Werff Ten Bosch, et al.

(2021) PEDIATRIC RESEARCH. 89(7). p.1695-1705

Add to list

Journal Article
A2
open access

Leukaemic stem cells in AML : where are we now? An update on recent findings and detection

Barbara Depreter, Barbara De Moerloose (UGent) , Jan Philippé (UGent) and Tim Lammens (UGent)

(2020) BELGIAN JOURNAL OF HEMATOLOGY. 11(6). p.246-252

Add to list

PhD Thesis
open access

Exploring the molecular and phenotypical heterogeneity between patients with pediatric acute myeloid leukemia

Barbara Depreter

(2020)

Add to list

Journal Article
A1
open access

Clinical significance of TARP expression in pediatric acute myeloid leukemia

Barbara Depreter, Barbara De Moerloose (UGent) , Karl Vandepoele (UGent) , Anne Uyttebroeck, An Van Damme, Barbara Denys, Laurence Dedeken, Marie-Françoise Dresse, Jutte Van Der Werff Ten Bosch, Mattias Hofmans (UGent) , et al.

(2020) HEMASPHERE. 4(2).

Add to list

Journal Article
A1
open access

TARP is an immunotherapeutic target in acute myeloid leukemia expressed in the leukemic stem cell compartment

Barbara Depreter, Karin Weening (UGent) , Karl Vandepoele (UGent) , Magnus Essand, Barbara De Moerloose (UGent) , Maria Themeli, Jacqueline Cloos, Diana Hanekamp, Ine Moors (UGent) , Inge D'hont (UGent) , et al.

(2020) HAEMATOLOGICA. 105(5). p.1306-1316

Academic Bibliography

Barbara Depreter

Nidogen-1, a player in KMT2A-rearranged pediatric acute myeloid leukemia

Nidogen-1, a novel player in KMT2A-rearranged pediatric acute myeloid leukemia patients, expressed in the leukemic stem cell

Ultra-deep sequencing and single cell multi-omics characterize measurable residual disease and identify therapy-survived clone in pediatric acute myeloid leukemia

Deciphering the non-coding landscape of pediatric acute myeloid leukemia

TARP as antigen in cancer immunotherapy

Deciphering molecular heterogeneity in pediatric AML using a cancer vs. normal transcriptomic approach

Leukaemic stem cells in AML : where are we now? An update on recent findings and detection

Exploring the molecular and phenotypical heterogeneity between patients with pediatric acute myeloid leukemia

Clinical significance of TARP expression in pediatric acute myeloid leukemia

TARP is an immunotherapeutic target in acute myeloid leukemia expressed in the leukemic stem cell compartment

Contents

Support

Contact